Literature DB >> 8733693

Serum HLA class I antigen levels in allogeneic bone marrow transplantation: a possible marker of acute GVHD.

F Puppo1, S Brenci, M Ghio, D Bignardi, P Contini, A Bacigalupo, M T Van Lint, M Scudeletti, S Ferrone, F Indiveri.   

Abstract

The levels of serum HLA class I antigens were determined at weekly intervals up to 5 weeks in 46 patients who had undergone allogeneic BMT. In patients with GVHD grade I or with GVHD grade I and fever of unknown origin (FUO), serum HLA class I antigen levels did not change during the observation period. In patients with GVHD grade II-IV serum HLA class I antigen level significantly increased in the week before the onset of GVHD, was maximal at the onset of GVHD and then persisted unchanged in the following 2 weeks. In patients with GVHD grade I or GVHD grade II-IV and infections whose onset coincided with that of acute GVHD a significant increase of serum HLA class I antigen level was found 2 weeks after the onset of the infectious episode. An increase of serum HLA class I antigen level was also found before the onset of repetitive GVHD grade II-IV episodes as well as during and after infectious episodes whose onset occurred after the onset of acute GVHD. The mean +/- s.d. concentrations of serum HLA class I antigens during GVHD grade II-IV episodes (9.4 +/- 3.4 micrograms/ml) and 2 weeks after the onset of infectious episodes (7.1 +/- 1.6 micrograms/ml) are significantly (P < 0.01 and P < 0.05, respectively) higher than that found 2 weeks before the onset of GVHD (3.0 +/- 0.5 micrograms/ml). The results of the present investigation suggest that measurement of serum HLA class I antigen level may be a possible marker to detect an acute GVHD following BMT.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8733693

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  2 in total

1.  Inhibition of Epstein-Barr virus (EBV)-specific CD8+ cytotoxic T lymphocyte (CTL) activity by soluble HLA class I in vitro.

Authors:  B Gansuvd; M Hagihara; B Munkhbat; N Kanai; N Morita; N Munkhtuvshin; J Chargui; S Kato; T Hotta; K Tsuji
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

2.  Soluble human leucocyte antigen-G molecules in peripheral blood haematopoietic stem cell transplantation: a specific role to prevent acute graft-versus-host disease and a link with regulatory T cells.

Authors:  A Le Maux; G Noël; B Birebent; J-M Grosset; N Vu; S De Guibert; M Bernard; G Semana; L Amiot
Journal:  Clin Exp Immunol       Date:  2008-01-28       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.